SOMCL-863 is a selective and orally active c-Met inhibitor with antitumor activity in vitro and in vivo. SOMCL-863 can be utilized in cancer research.
Products | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > c-Met/HGFR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.